Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study

Affiliation auteurs!!!! Error affiliation !!!!
TitreRituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study
Type de publicationJournal Article
Year of Publication2014
AuteursDelfau-Larue M-H, Wolfram K, Berger F, Jardin F, Briere J, Thieblemont C, Feugier P, Haioun C, Salles GAndre, Ribrag V, Casasnovas R-O, Unterhalt M, Dreyling M, Pott C, Macintyre E, Hermine O, Hoster E
JournalBLOOD
Volume124
Date PublishedDEC 6
Type of ArticleMeeting Abstract
ISSN0006-4971